{"id":"NCT00930176","sponsor":"Bio Products Laboratory","briefTitle":"A Study Investigating Treatment Factor X in People With Factor X Deficiency","officialTitle":"A Phase III Open, Multicentre Study to Investigate the Pharmacokinetics, Safety and Efficacy of BPL's High Purity Factor X in the Treatment of Severe and Moderate Factor X Deficiency.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-01","primaryCompletion":"2013-11","completion":"2013-11","firstPosted":"2009-06-30","resultsPosted":"2014-12-12","lastUpdate":"2014-12-12"},"enrollment":16,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Factor X Deficiency"],"interventions":[{"type":"BIOLOGICAL","name":"Human Coagulation FACTOR X","otherNames":[]}],"arms":[{"label":"Human Coagulation FACTOR X","type":"EXPERIMENTAL"}],"summary":"The main objective of the study is to assess the pharmacokinetics of FACTOR X after a single dose of 25IU/kg.\n\nThe secondary objectives of the study are to assess efficacy and safety of FACTOR X in the treatment of bleeding episodes over at least 6 months.","primaryOutcome":{"measure":"FX:C Incremental Recovery","timeFrame":"At Baseline (during first 60 minutes post-dose) and at 6 months post-Baseline (during first 60 minutes post-dose)","effectByArm":[{"arm":"Human Coagulation FACTOR X","deltaMin":2.07,"sd":21.01}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":11},"locations":{"siteCount":14,"countries":["United States","Germany","Spain","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["29545231"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":16},"commonTop":["Headache","Nasopharyngitis","Back pain","Pain in extremity","Arthralgia"]}}